Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
DUBLIN, Nov. 12, 2025 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging......